Resolution of ischemia with β-blocker in a patient with anomalous right coronary artery

Sanjay Kumar1, Sashank Kaushik, Alain Vaval

  • 1Cardiovascular Medicine Department, State University of New York Downstate Medical Center, Brooklyn, New York, United States.

BMJ Case Reports
|June 8, 2012
PubMed

Insights

An anomalous origin of the right coronary artery (RCA) can cause serious heart issues. This case shows long-term beta-blocker therapy successfully resolved ischemia in an anomalous RCA patient.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Clinical Medicine

Background:

  • Anomalous origin of the right coronary artery (RCA) is a rare congenital heart defect.
  • It is often linked to significant cardiovascular events such as angina, myocardial infarction, and sudden cardiac death.
  • Surgical intervention is frequently considered the primary treatment for symptomatic anomalous RCA.

Observation:

  • The study presents a case of anomalous RCA.
  • The patient experienced symptoms suggestive of myocardial ischemia.
  • Serial stress testing was employed for objective assessment.

Findings:

  • Long-term beta-blocker therapy was initiated as an alternative to surgery.
  • Objective evidence from serial stress testing demonstrated a resolution of ischemia.
  • This suggests a non-surgical management approach can be effective.

Implications:

  • Beta-blocker therapy may be a viable alternative to surgery for select patients with anomalous RCA.
  • Objective stress testing is crucial for monitoring treatment efficacy.
  • This finding could influence clinical decision-making for anomalous coronary artery origins.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...